Panaxia Labs Israel Ltd
Panaxia Pharmaceutical Industries Ltd provides pharmaceutical solutions for patients and physicians. The company offers pharma-grade smokeless cannabis products, such as oral and sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches. Panaxia Pharmaceutical Industries Ltd has strategic partnerships with Ultra Health,… Read more
Panaxia Labs Israel Ltd (HROD) - Total Assets
Latest total assets as of June 2019: ILA11.33 Million ILA
Based on the latest financial reports, Panaxia Labs Israel Ltd (HROD) holds total assets worth ILA11.33 Million ILA as of June 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panaxia Labs Israel Ltd - Total Assets Trend (2015–2018)
This chart illustrates how Panaxia Labs Israel Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panaxia Labs Israel Ltd - Asset Composition Analysis
Current Asset Composition (December 2018)
Panaxia Labs Israel Ltd's total assets of ILA11.33 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 92.8% |
| Accounts Receivable | ILA85.00K | 0.5% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA17.00K | 0.1% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2015–2018)
This chart illustrates how Panaxia Labs Israel Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panaxia Labs Israel Ltd's current assets represent 98.8% of total assets in 2018, an increase from 85.0% in 2015.
- Cash Position: Cash and equivalents constituted 92.8% of total assets in 2018, up from 83.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Panaxia Labs Israel Ltd Competitors by Total Assets
Key competitors of Panaxia Labs Israel Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
XIWANG SPECIAL STEE (2XI.SG)
STU:2XI
|
Germany | €15.07 Billion |
|
LINDT & SPRUENGLI N - Dusseldorf Stock Exchang
DU:LSPN
|
Germany | €7.86 Billion |
|
PRICELINE.COM
BE:PCE1
|
Germany | €27.98 Billion |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
Germany | €27.98 Billion |
|
MURPHY USA
BE:1MU
|
Germany | €4.40 Billion |
|
RESMED (RME.SG)
STU:RME
|
Germany | €7.22 Billion |
|
DIOS EXPLORATIONS
BE:BFM
|
Germany | €7.25 Million |
|
CHINA YUCHAI INTL (CYD.SG)
STU:CYD
|
Germany | €25.76 Billion |
Panaxia Labs Israel Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Panaxia Labs Israel Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Panaxia Labs Israel Ltd is currently not profitable relative to its asset base.
Panaxia Labs Israel Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | 2.78 | 2.78 |
| Quick Ratio | 0.36 | 2.78 | 2.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-11.46 Million | ILA 11.44 Million | ILA 11.44 Million |
Panaxia Labs Israel Ltd - Advanced Valuation Insights
This section examines the relationship between Panaxia Labs Israel Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -32.9% |
| Total Assets | ILA18.08 Million |
| Market Capitalization | $112.83K USD |
Valuation Analysis
Below Book Valuation: The market values Panaxia Labs Israel Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Panaxia Labs Israel Ltd's assets decreased by 32.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Panaxia Labs Israel Ltd (2015–2018)
The table below shows the annual total assets of Panaxia Labs Israel Ltd from 2015 to 2018.
| Year | Total Assets | Change |
|---|---|---|
| 2018-12-31 | ILA18.08 Million | -32.88% |
| 2017-12-31 | ILA26.93 Million | -8.97% |
| 2016-12-31 | ILA29.59 Million | -14.23% |
| 2015-12-31 | ILA34.50 Million | -- |